Boryeong Anticancer Drug Research Subsidiary 'Liquon' Selected for National Support Project for Global Expansion

[Asia Economy Reporter Kwanju Lee] RECUON, an anticancer drug research and development (R&D) subsidiary of Boryung (formerly Boryung Pharmaceutical), announced on the 26th that it has been selected for the "Pharmaceutical Industry Full-Cycle Global Expansion Support Project" organized by the Korea Health Industry Development Institute (KHIDI).

This project is conducted by KHIDI under the commission of the Ministry of Health and Welfare, providing tailored support throughout the entire pharmaceutical industry cycle?from business planning to localization?to enhance the global competitiveness of domestic pharmaceutical companies and ensure successful entry into overseas markets.

With this selection, RECUON has been chosen as a recipient of the "Full-Cycle Overseas Expansion Consulting" support, receiving funding for consulting costs covering the entire cycle including global clinical trials, regulatory approval, and licensing. Accordingly, the company expects to accelerate the registration of its core pipeline 'BR101801 (project name BR2002)' as an orphan drug in the development stage with the Ministry of Food and Drug Safety and its designation as an orphan drug by the U.S. Food and Drug Administration (FDA).

BR101801 is a lymphoma treatment agent that simultaneously inhibits three key growth and regulatory factors of cancer cells: PI3K gamma, PI3K delta, and DNA-PK. It passed the Phase 1a clinical trial last year, where among nine patients with peripheral T-cell lymphoma (PTCL), one achieved a complete response and two achieved partial responses.

RECUON is currently conducting Phase 1b and Phase 2 clinical trials simultaneously targeting PTCL patient groups in the United States and Korea. Recently, it also received approval for an Investigational New Drug (IND) application in Taiwan. Bongseok Kim, CEO of RECUON, stated, "Being selected for this support project has given new momentum to the development and commercialization of BR101801. We will not only improve treatment outcomes for cancer patients through differentiated innovative drug development but also lead global expansion."